What’s happening to generic drug prices? March 2020 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” We saw more price increases than decreases this past month. Also, for the second month in a row, we saw an increase in annualized spending based on typical utilization trends. It is becoming clear that the generic marketplace is not providing the deflation and efficiency that we have become accustomed to in recent years. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for important updates on the latest generic drug price changes, plus an updated NADAC Packed Bubble Chart.

Ben LinkMarch 24, 2020NADAC, Medicaid, Generic, Gleevec, Imatinib, COVID, Naproxen, Hydroxychloroquine

What’s happening to generic drug prices? February 2020 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” We saw more price increases than decreases this past month, and for the first time in eight months, an increase in annualized spending based on typical utilization trends. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for important updates on the latest generic drug price changes, plus an updated NADAC Packed Bubble Chart.

Ben LinkMarch 9, 2020NADAC, Medicaid, Generic, Buprenorphine-Naloxone, Gleevec, Imatinib, Zantac, Ranitidine, Zomig, Zolmitriptan, GoodRx, AWP, Drug List Price, ICER

What’s happening to generic drug prices? October 2019 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” We saw a lot of price increases this past month, but an overall decrease in annualized spending. As always, the details matter, and we’re here to provide them for you. For those that have followed previous 46brooklyn reports, there are several familiar drugs that experienced significant pricing movement this past month, so this piece will be a good trip down memory lane. Check out our latest drug pricing report for a lot of important updates, plus an updated NADAC Packed Bubble Chart.

Ben LinkOctober 31, 2019NADAC, Medicaid, Generic, Gleevec, Imatinib, Spread, Glumetza, Metformin, Prograf, Massachusetts, Tacrolimus, Xeloda, Capecitabine

What’s happening to generic drug prices? July 2019 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” We saw a lot of price increases this past month, and an overall decrease in annualized spending, after a couple months of concerning trends. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates, plus an updated NADAC Packed Bubble Chart.

What’s happening to generic drug prices? January 2019 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” On a positive note, it looks like there was a substantial amount of generic deflation in the aggregate. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates, plus an updated and upgraded NADAC Packed Bubble Chart!

Ben LinkJanuary 25, 2019NADAC, Medicaid, ADHD, Concerta, Methylphenidate, Gleevec, Imatinib

Does Pennsylvania have a spread pricing problem?

As drug pricing scrutiny grows, PBM spread pricing of cheap, generic drugs is becoming a hot topic of conversation in states across the country. After the state of Ohio opened the books thanks to an audit from the state auditor, the uncovered $224 million PBM spread now has other states scrambling to see what they are being charged as well. One of those states is Pennsylvania, where their state auditor is trying hard to get the data he needs to see where the money is going in the third largest managed care program in the country. Since there are many folks wondering what’s going on in Pennsylvania, considering the current lack of hard data, we decided to dig into the publicly available data to see if Pennsylvania appears to have the makings of an “Ohio problem.”

Ben LinkDecember 5, 2018Pennsylvania, Gleevec, Imatinib, Capecitabine, Seroquel, Ohio, Spread, Xeloda, NADAC, Quetiapine

What's happening to generic drug prices? - September 2018 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our second installment of “what happened to generic drug prices last month.” Good news. Prices are dropping significantly. Check out our latest drug pricing report for lots of important updates, plus an updated NADAC Packed Bubble Chart!

Ben LinkSeptember 20, 2018HIV, NADAC, Reyataz, Gleevec, Imatinib, Tamiflu, Suboxone, Concerta, Viagra

We're live.

Drug prices are complicated. Let’s simplify them. Today, we are pleased to announce the launch of 46brooklyn, a research and analytics project to help bring transparency to prescription drug prices and provide patients and key stakeholders the tools necessary to hold the system accountable.

Ben LinkAugust 1, 2018Gleevec, Imatinib, Axios